Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDROSERPINE PLUS (R-H-H) vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines from peripheral sympathetic nerve endings, reducing sympathetic tone. Hydralazine directly relaxes arteriolar smooth muscle, decreasing systemic vascular resistance.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension
Hypertension
1 tablet orally twice daily. Each tablet contains hydrochlorothiazide 25 mg, reserpine 0.125 mg, and hydralazine hydrochloride 25 mg.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Hydroflumethiazide: 2-3 h; reserpine: 50-100 h (biphasic); hydralazine: 2-4 h (fast acetylators), 6-8 h (slow acetylators).
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Hydrochlorothiazide: Not metabolized, excreted unchanged in urine. Reserpine: Metabolized in the liver via hydrolysis and conjugation. Hydralazine: Acetylation in the liver via N-acetyltransferase (NAT2).
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Hydroflumethiazide: renal (50-65% unchanged); reserpine: renal (30%) and fecal (60%) as metabolites; hydralazine: renal (85% as metabolites, 10% unchanged).
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Hydroflumethiazide: 70% (albumin); reserpine: 96%; hydralazine: 87% (albumin and alpha-1 acid glycoprotein).
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Hydroflumethiazide: 3.6 L/kg; reserpine: 10-20 L/kg; hydralazine: 1.6 L/kg (central) and 2.7 L/kg (total).
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral: hydroflumethiazide 70-75%; reserpine 50-60%; hydralazine 30-50% (first-pass metabolism).
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For Cr Cl 30-50 m L/min: reduce dose to 1 tablet orally once daily; monitor electrolytes. No adjustment needed for Cr Cl >50 m L/min.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For Child-Pugh class A or B: use with caution; reduce dose to 1 tablet orally once daily and monitor for encephalopathy.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not recommended for pediatric use due to lack of safety and efficacy data.
Not established; avoid use in children.
Start with 1 tablet orally once daily; titrate slowly. Monitor for orthostatic hypotension, electrolyte imbalances, and CNS effects. Avoid use in patients with depression.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
Reserpine: May cause mental depression, especially in patients with a history of depression. Discontinue at first signs of depression.
None
Hydrochlorothiazide: Electrolyte imbalance, hyperglycemia, hyperuricemia, lupus exacerbation. Reserpine: Mental depression, peptic ulcer, bradycardia. Hydralazine: Drug-induced lupus, tachycardia, myocardial ischemia, peripheral neuritis.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Reserpine: Hypersensitivity, history of depression, active peptic ulcer, ulcerative colitis, pheochromocytoma. Hydralazine: Hypersensitivity, mitral valve rheumatic heart disease, coronary artery disease. Hydrochlorothiazide: Anuria, hypersensitivity to sulfonamides, severe renal failure.
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach) due to the potassium-sparing effect of the combination? Note: Actually HYDROSERPINE PLUS contains hydrochlorothiazide which is potassium-wasting; reserpine and hydralazine do not affect potassium significantly. Thus, potassium supplementation may be needed; monitor potassium levels. Limit sodium intake to control blood pressure. Avoid tyramine-rich foods (e.g., aged cheeses, cured meats) due to reserpine's potential to cause hypertensive crisis? Reserpine is not a MAOI, but caution with high-tyramine foods is advised.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
First trimester: Hydrochlorothiazide is associated with an increased risk of neural tube defects and oral clefts; reserpine may cause respiratory distress; hydralazine is not teratogenic in animal studies. Second and third trimesters: Hydrochlorothiazide may cause fetal electrolyte disturbances and thrombocytopenia; reserpine may cause neonatal bradycardia and hypotension; hydralazine may cause fetal hypotension and reflex tachycardia.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Hydrochlorothiazide is excreted in breast milk in low concentrations (M/P ratio 0.6); reserpine is excreted (M/P ratio unknown, but may cause galactorrhea and infant sedation); hydralazine is excreted in low amounts (M/P ratio not well defined). Theoretical risk of hypotensive effects in infants. Caution recommended.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
No specific dose adjustments have been established for the combination; however, increased plasma volume and renal clearance in pregnancy may reduce efficacy, potentially requiring dose increase or alternative therapy. Individualize based on blood pressure response and avoid volume depletion.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
Hydralazine and hydrochlorothiazide can cause lupus-like syndrome; monitor for arthralgias, rash, and fever. Reserpine depletes catecholamines, leading to potential sedation and depression; use with caution in patients with history of mood disorders. Check serum potassium and uric acid levels due to thiazide component.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take this medication exactly as prescribed; do not skip doses or double up.,Rise slowly from sitting or lying down to prevent dizziness.,Avoid driving or operating machinery until you know how this drug affects you.,Report any unusual weight gain, swelling, or shortness of breath.,Contact your doctor if you experience joint pain, fever, or rash.,Do not stop taking this medicine abruptly; it may cause blood pressure to rise.,Limit alcohol consumption as it can increase dizziness and drowsiness.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDROSERPINE PLUS (R-H-H) vs ALDORIL 25, answered by our medical review team.
HYDROSERPINE PLUS (R-H-H) is a Antihypertensive Combination that works by Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines from peripheral sympathetic nerve endings, reducing sympathetic tone. Hydralazine directly relaxes arteriolar smooth muscle, decreasing systemic vascular resistance.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDROSERPINE PLUS (R-H-H) and ALDORIL 25 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDROSERPINE PLUS (R-H-H) is: 1 tablet orally twice daily. Each tablet contains hydrochlorothiazide 25 mg, reserpine 0.125 mg, and hydralazine hydrochloride 25 mg.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDROSERPINE PLUS (R-H-H) and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDROSERPINE PLUS (R-H-H) is classified as Category C. First trimester: Hydrochlorothiazide is associated with an increased risk of neural tube defects and oral clefts; reserpine may cause respiratory distress; hydralazine is not terat. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.